Publication:
Pharmacological treatment for the novel coronavirus disease 2019 (COVID-19 infection)

Simple item page
dc.contributor.authorNattapong Tidwongen_US
dc.contributor.authorPreecha Montakantikulen_US
dc.contributor.authorWeerawat Manosuthien_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherChiang Mai Universityen_US
dc.contributor.otherBamrasnaradura Infectious Diseases Instituteen_US
dc.date.accessioned2020-06-02T05:22:48Z
dc.date.available2020-06-02T05:22:48Z
dc.date.issued2020-01-01en_US
dc.description.abstract© Faculty of Pharmacy, Mahidol University (Thailand) 2020. As of March 22, 2020, a total of 292,142 confirmed coronavirus disease 2019 (COVID-19) cases have been reported globally. Although there are currently no specific antiviral agents but all coronaviruses shared similar key elements of target for currently approved antiviral or new drug development. Several agents might be considered as a possible treatment based on the efficacy in SARS and MERS.en_US
dc.identifier.citationPharmaceutical Sciences Asia. Vol.47, No.2 (2020), 97-103en_US
dc.identifier.doi10.29090/psa.2020.02.020.0026en_US
dc.identifier.issn25868470en_US
dc.identifier.issn25868195en_US
dc.identifier.other2-s2.0-85085214601en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/56310
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85085214601&origin=inwarden_US
dc.subjectMedicineen_US
dc.subjectPharmacology, Toxicology and Pharmaceuticsen_US
dc.titlePharmacological treatment for the novel coronavirus disease 2019 (COVID-19 infection)en_US
dc.typeReviewen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85085214601&origin=inwarden_US

Files

Collections

Scopus 2020